Harmony Biosciences Holdings, Inc.
Orexin-2 receptor agonist (BP1.15205)
Resolved
7days ago
Phase 1 readout · Jun 30, 2026
What's at stake
Phase 1 trial results for Orexin-2 receptor agonist (BP1.15205) in its lead indication are due Jun 30, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 14h ago
“Orexin-2 receptor agonist (BP1.15205) o Phase 1 clinical PK data in mid-2026”